LAS VEGAS, February 22, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
Insomniais a common issue among people today and several factors contribute to sleeping issues like stress, diet, chronic pain, asthma or nasal/sinus issues. Sleeping pills are a traditional solution but come with unwanted side effects and can comprise overall
Cannabidiol (CBD) is a natural alternative to sleeping pills is now legalized in several states across America. CBD works with the body's endocannabinoid system, accountable for all the homeostatic functions of the body. CBD regulates balance and homeostasis in the human body. Additionally, CBD is an anti-anxiolytic which fights off anxiety, a huge influence in horrible sleep patterns.
REM sleep plays a major role in keeping up with health because it's during REM when your blood flows and diverts to your muscles, giving time and space for your brain to take a break. Without consistent REM sleep, your brain is not getting the rest that it needs. Researchers have released favorable data in the role of CBD in the REM sleep phase and believe CBD is successful in regulating REM sleep.
This information is exciting for those suffering from insomnia. CBD could have a more effective role in sleep regulation and is more natural than addictive, tolerance-building sleeping pills. As these are early findings that need to be followed up with more studies on humans, the research is pointing toward CBD as a natural sleep supplement.
In other CBD and marijuana news, check out these companies: NightFood Holdings, Inc. (OTC: NGTF), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, Inc. (NASDAQ: INSY), Terra Tech Corp. (OTC: TRTC), and General Cannabis Corp. (OTC: CANN).
NightFood Holdings, Inc. (OTC: NGTF)
Market Cap: $19.35M, current share price: $.599
Dr. Michael Breus has joined the team at NGTF, the category leading, better-for-you, sleep-friendly nighttime snack company. Known as the "The Sleep Doctor™," Dr. Breus frequently appears in the national media to educate and inform consumers on ways they can sleep better in order to lead healthier, more productive lives. His television appearances span several popular shows including Dr. Oz, Oprah, The View, and The Today Show and he frequently writes for both Psychology Today and The Huffington Post. NGTF is excited to have Dr. Breus on the team to as a scientific advisor in the launch of additional products and snack formats. He will also help NGTF to communicate the importance of proper night snacking and the impact of evening nutritional choices on sleep.
GW Pharmaceuticals plc (NASDAQ: GWPH)
Market Cap: $3.633B, current share price: $130.83
GWPH released operational highlights earlier this month. The biopharmaceutical company is focused on discovering, developing and commercializing novel therapeutics based off their novel therapy, Epidiolex. With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year FDA decision date, 2018 is expected to be an exciting year for GWPH with an anticipated first U.S. approval and launch.
INSYS Therapeutics, Inc. (NASDAQ: INSY)
Market Cap: $556.473M, current share price: $7.59
A leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, INSY announced today that both their CEO and CFO will present at the RBC Capital Markets Global Healthcare Conference. Saeed Motahari (CEO) and Andrew Long (CFO) will present together on February 22nd, 2018 at 10am and the presentation will webcast live. To access the presentation, go to the Investors section of company's website at https://www.insysrx.com/, under Presentations & Events.
Terra Tech Corp. (OTCQX: TRTC)
Market Cap: $264.76M, current share price: $.27355
TRTC has expanded retail operations into Santa Ana, Southern California, through the acquisition of the assets of Tech Center Drive Management LLC. This operated The Reserve OC medical cannabis dispensary and is currently rebranded as a Blüm dispensary. Blüm is a subsidiary of TRTC and its retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions.
General Cannabis Corp. (OTCQB: CANN)
Market Cap: $142.533M, current share price: $4.25
The comprehensive national resource to the regulated cannabis industry, CANN, announced today the Company's revenue results for the quarter ended December 31, 2017. For the three months ending on December 31, 2017, the Company reported their highest quarterly revenues ever of approximately $990,000. Annual revenues in 2017 increased to approximately $3,522,000 compared to the annual 2016 revenues of approximately $2,982,000.
From an analysis of companies working with CBD and marijuana, there are many potential avenues for CBD to infiltrate the market.
Website: http://microcapspeculators.com/ For Full Legal Disclaimer Click Here.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Content Provided By: Microcap Speculators Email: email@example.com Phone: +1-702-720-6310 Media Contact FN Media Group LLC e-mail: firstname.lastname@example.org +1(954)345-0611
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All